Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414936 | 0.87 | NAMPT (0.42) | KITGRM5NAMPTKDM4EP2RX7 | |
| SCHEMBL3414781 | 0.85 | GRM5 (0.49) | KITGRM5NAMPTKDM4EP2RX7 | |
| SCHEMBL3414939 | 0.84 | NAMPT (0.47) | KITGRM5NAMPTKDM4EP2RX7 | |
| SCHEMBL3414785 | 0.84 | NPC1 (0.41) | GRM5KDM4E | |
| SCHEMBL3413088 | 0.84 | GRM5 (0.58) | KITGRM5KDM4E | |
| SCHEMBL3414822 | 0.83 | GRM5 (0.49) | KITGRM5NAMPTKDM4E | |
| SCHEMBL3413404 | 0.81 | NAMPT (0.47) | KITGRM5NAMPTKDM4E | |
| SCHEMBL3414919 | 0.80 | GRM5 (0.50) | KITGRM5 | |
| SCHEMBL3411310 | 0.80 | KIT (0.44) | KITGRM5NAMPTTACR2TACR1 | |
| SCHEMBL3413220 | 0.80 | KIT (0.44) | KITGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | claimed |
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | GRM5, GRM1, GRM2 | KIT 4672/4885GRM5 1/4885NAMPT 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.